Femarex (Letrozole) is a nonsteroidal selective inhibitor of the third-generation aromatase. The structure and activity similar to the active drug Arimidex (Anastrazole) and assigned for the same indications. In particular, letrozole is recommended for the treatment of post-menopausal syndrome with estrogen receptor-positive or estrogen receptor-unknown breast cancer. Generally used as the drug of choice second line therapy after an unsuccessful estrogen receptor antagonist tamoxifen, although, depending on the circumstances, and may be selected as a first line drug. Male bodybuilders and other athletes have found their own benefit in the use of letrozole, thanks to its ability to mitigate / eliminate estrogenic side effects associated with taking aromatizing anabolic-androgenic steroids, such as:. Gynecomastia, increased body fat, water retention, etc.
Side effect Perhaps:
headache, nausea, peripheral edema, fatigue, hot flashes, thinning hair, skin rash, vomiting, dyspepsia, increased body weight, musculoskeletal pain, anorexia, vaginal bleeding, Leucorrhœa, constipation, dizziness, increased appetite, increased sweating . Rare: shortness of breath, thrombophlebitis, bleeding from the vagina.
Before starting treatment, it is desirable to study estrogenretseptornogo status. Feasibility destination patients without lymph node determined individually: takes into account the degree of malignancy, tumor size, presence of estrogen receptors age. The period of treatment is not suitable for driving et al. Activities requiring attention and reaction rate.